Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Muhammad Zubair Afzal"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Abstract Background Metformin is one of the biguanides commonly used in patients with type II Diabetes Mellitus. Apart from its hypoglycemic properties, metformin also inhibits the cell cycle by restricting protein synthesis and cell proliferation vi
Externí odkaz:
https://doaj.org/article/2fe1d935610345b7be975e47cac065f5
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of patients present with
Externí odkaz:
https://doaj.org/article/2f50bbafae1f4d488aace80186767302
Publikováno v:
J Thorac Dis
e21039 Background: Lung cancer is the leading cause of cancer-related death in the United States. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small-cell lung cancer (NSCLC). Denosumab is a humanized monoclonal antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21e4e8e480dae8933dbea140a67063df
https://europepmc.org/articles/PMC8411139/
https://europepmc.org/articles/PMC8411139/
Publikováno v:
Journal of Immunotherapy. 42:251-264
Local and systemic inflammation significantly effects tumor progression and its response to therapy. We aim to evaluate the prognostic significance of inflammatory cells, their ratios, and a change in these indices while patients are receiving immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2ba117e351e834e1dde13d5dec6368
https://doi.org/10.1097/cji.0000000000000272
https://doi.org/10.1097/cji.0000000000000272
Autor:
Keisuke Shirai, Muhammad Zubair Afzal
Publikováno v:
Journal of Immunotherapy. 42:136-141
Talimogene laherparepvec (T-VEC) is approved for unresected stage III-IV malignant melanoma. T-VEC has a direct cytotoxic effect and enhances the antitumor immunity of host cells. Immune checkpoints inhibitors also enhance the immunity of host cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e26c6c28f5edd2f8365290f401c5ff
https://doi.org/10.1097/cji.0000000000000265
https://doi.org/10.1097/cji.0000000000000265
Autor:
Muhammad Talha Khan, Muhammad Aamir, Muhammad Zubair Afzal, Fatima Ayub, Adil Cheema, Danish Thameem
Publikováno v:
Chest. 158:A2128-A2129
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8022f3f78a1bd8f6e391caf554033e63
https://doi.org/10.1016/j.chest.2020.08.1834
https://doi.org/10.1016/j.chest.2020.08.1834
Publikováno v:
Annals of translational medicine. 7(Suppl 1)
Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line therapy for advanced nonsquamous NSCLC. At the primary analysis (median follow-up time 10.6 months
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a82c3f20e1d1aebded44495424f6223
https://pubmed.ncbi.nlm.nih.gov/30138764
https://pubmed.ncbi.nlm.nih.gov/30138764
Autor:
John P. Palmer, Keisuke Shirai, Muhammad Zubair Afzal, Yenong Cao, Natasha Dhawan, Samer Ibrahim
Publikováno v:
Journal of Clinical Oncology. 39:e21202-e21202
e21202 Background: Increased systemic inflammatory state and increased inflammation within tumor micro-environment (TME) have been associated with a worse prognosis and lower responsiveness to immune checkpoint inhibitors (ICI). Systemic inflammatory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f559ccd788f830a5db19b41f3abf8c1
https://doi.org/10.1200/jco.2021.39.15_suppl.e21202
https://doi.org/10.1200/jco.2021.39.15_suppl.e21202
Autor:
Samer Ibrahim, Natasha Dhawan, Yenong Cao, Muhammad Zubair Afzal, John P. Palmer, Keisuke Shirai
Publikováno v:
Journal of Clinical Oncology. 39:e21137-e21137
e21137 Background: Immune checkpoint inhibitors (ICI) are the standard of care in the treatment of non-small cell lung cancer (NSCLC). ICIs are commonly used in combination with chemotherapy but may be used as monotherapy in selected cases. Registrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::907382b95d7fe20572a21fdaea39a5de
https://doi.org/10.1200/jco.2021.39.15_suppl.e21137
https://doi.org/10.1200/jco.2021.39.15_suppl.e21137
Autor:
Natasha Dhawan, John P. Palmer, Muhammad Zubair Afzal, Yenong Cao, Keisuke Shirai, Samer Ibrahim
Publikováno v:
Journal of Clinical Oncology. 39:e21209-e21209
e21209 Background: Immune checkpoint inhibitors (ICI) are now the standard of care in the treatment of non-small cell lung cancer (NSCLC). ICIs may be used as monotherapy or in combination with chemotherapy. Increased recruitment of inflammatory cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0643dd1968857070821e63f8a7653efe
https://doi.org/10.1200/jco.2021.39.15_suppl.e21209
https://doi.org/10.1200/jco.2021.39.15_suppl.e21209